Hiv clinical plan
AssigneeExcision Biotherapeutics, Inc.
InventorThomas MALCOLM
Life of this patent
Estimating the term…
Abstract
A method of performing a clinical trial for a gene editing or gene excising system for treating HIV in humans, by recruiting HIV infected individuals currently receiving highly active antiretroviral therapy (HAART) that is effective in lowering viral load and entering qualified individuals as participants in a clinical trial, administering the gene editing or gene excising system treatment to the participants in Phase 1a, Phase 1b, and Phase 1c, and performing assays to confirm HIV viral genome excision from the participants' cells. A method of performing a clinical trial for a gene editing or gene excising system for treating a latent viral infection in humans.
Claims36
A method of performing a clinical trial for a gene editing or gene excising system for treating HIV in humans, including the steps of:
- recruiting HIV infected individuals currently receiving highly active antiretroviral therapy (HAART) that is effective in lowering viral load and entering qualified individuals as participants in a clinical trial;
- administering a gene editing or gene excising system treatment to the participants in Phase 1a, Phase 1b, and Phase 1c clinical trials;
- and
- performing assays to confirm HIV viral genome excision from the participants' cells.
A method of performing a clinical trial for a gene editing or gene excising system for treating a latent viral infection in humans, including the steps of:
- recruiting infected individuals and entering qualified individuals as participants in a clinical trial;
- administering a gene editing or gene excising system treatment to the participants in Phase 1a, Phase 1b, and Phase 1c clinical trials;
- and
- performing assays to confirm viral genome excision from the participants' cells.
Dependencies are inferred from the claim text.